Remove Clinical Supply Remove Licensing Remove Pharmaceuticals
article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

Regulatory Excellence - Licenses for Schedule I through IV drug substances. Adherence to harmonized pharmacy-specific SOPs based on cGMP principles at our three clinical pharmacology units. Electronic security access to the pharmacy and video monitoring. - 24/7 monitoring of temperature and humidity.

article thumbnail

Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420

The Pharma Data

MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. MP0420 is designed to bind the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells.

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer

The Pharma Data

Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases. PharmaDrug Inc.

FDA 52
article thumbnail

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. During the clinical development stage, Molecular Partners will provide clinical supply.

article thumbnail

The golden era of GLP-1 drugs: How will it impact medicine and society?

BioPharma Drive: Drug Pricing

Also, we should not rely solely on pharmaceuticals to address the root causes of systemic health issues. These drugs could drastically lower rates of many life-affecting diseases and ailments, such as diabetes, cardiovascular disease and other metabolic disorders and contribute to improving millions of lives.

article thumbnail

FDA’s AI tool ‘Elsa’ is here, and the industry has questions

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

FDA 130
article thumbnail

[Podcast] Trial Trailblazers: Behind clinical breakthroughs

BioPharma Drive: Drug Pricing

But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

Trials 130